Exploration of Targeted Anti-tumor Therapy

Table 1

Summary of evidence for most promising methylation biomarkers for diagnosis of CRC in tissue (sensitivity > 75%)

Biomarker gene(s)	Sensitivity (%)	Specificity (%)	Reference
AKR1B1, SEPT9	98	99	[23]
APC, MGMT, RASSF2A, WIF1	87	92	[22]
APC, p16^INK4a, MGMT, RARB2	77	100	[24]
BMP3	84	95	[25]
CDH1	87	74	[26]
CMTM3, MDFI, SSTR2	81	91	[27]
CNRIP1, FBN1, INA, MAL, SNCA, SPG20	94	98	[21]
GDNF, SNAP91, NDRG4	86	96	[28]
EFHD1	79	78	[29]
ITGA4	89	88	[30]
NDRG4	81–92	92–95	[25, 31]
MGMT, RASSF1A, SEPT9	97	74	[11]
SEPT9	78–97	96–97	[32, 33]
SFRP1	93	100	[34]
SFRP2	83–91	100	[35, 36]
SPG20	94	99	[21]
TFPI2	99	94	[10]
VIM	86	95	[37]

Return to article view

AKR1B1: aldo-keto reductase family 1 member B; SEPT9: septin 9; RARB2: retinoic acid receptor beta 2; BMP3: bone morphogenetic protein 3; CDH1: cadherin 1; CMTM3: CKLF like MARVEL transmembrane domain containing 3; MDFI: myoD family inhibitor; SSTR2: somatostatin receptor 2; GDNF: glial cell derived neurotrophic factor; SNAP91: synaptosome associated protein 91; NDRG4: NDRG family member 4; EFHD1: EF-hand domain family member D1; ITGA4: integrin subunit alpha 4; VIM: vimentin